Faron Pharmaceuticals (FARON.HE)

Executive Summary

Faron Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel cancer immunotherapies that harness the patient's immune system. Its lead asset, bexmarilimab (FP-1305), is a humanized monoclonal antibody targeting CLEVER-1, a receptor on immunosuppressive macrophages, thereby reprogramming the tumor microenvironment to enhance anti-tumor immunity. Despite several terminated or withdrawn trials in indications such as renal cell carcinoma and non-small cell lung cancer, Faron is advancing bexmarilimab in acute myeloid leukemia (AML) and soft tissue sarcoma. The most advanced ongoing trial is a Phase 1/2 study combining bexmarilimab with azacitidine and venetoclax in relapsed/refractory AML and myelodysplastic syndromes (NCT05428969), which completed enrollment in April 2026, with data readout imminent. A Phase 1/2 trial of bexmarilimab plus doxorubicin in soft tissue sarcoma is set to begin recruitment in July 2026.

Upcoming Catalysts (preview)

• Q3 2026Data readout from AML combination trial (NCT05428969)40% success
• Q3 2026Initiation of soft tissue sarcoma trial (bexmarilimab + doxorubicin)80% success
• TBDPotential partnership or licensing deal for bexmarilimab30% success